NVDA
NVIDIA
-- 112.690 TSLA
Tesla
-- 262.670 AVGO
Broadcom
-- 194.960 PLTR
Palantir
-- 84.910 GRRR
Gorilla Technology
-- 28.410 
NEWS
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
IO Biotech announced promising Phase 2 results for its cancer vaccine IO102-IO103 combined with KEYTRUDA® in first-line metastatic lung cancer treatment. The study showed a 55% unconfirmed/48% confirmed overall response rate and 81% disease control rate in NSCLC patients. About 50% of patients showed no disease progression at 12 months, with median progression-free survival of 8.1 months. The safety profile remained consistent with previous studies, mainly showing low-grade injection site reactions. The company also presented pre-clinical data for IO112, their second T-win vaccine candidate targeting arginase 1, demonstrating anti-tumor activity.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment